[1] 朱明清,耿美菊,陈黎,等.多发性骨髓瘤的免疫表型特征[J]. 白血病.淋巴瘤,2006,15(5):347-348.
[2] Kumar S,Kimlinger T,Morice W. Immunophenotyping in multiple myeloma and related plasma cell disorders[J]. Best Pract Res Clin Haematol,2010,23( 3) : 433-451.
[3] Medina F, Segundo C, Campos C A, et al. The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increased maturity but local profiles of adhesion molecule expression[J]. Blood, 2002,99(6):2154-2161.
[4] Lin P, Owens R, Tricot G, et al. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma[J]. Am J Clin Pathol,2004,121:482-488.
[5] Seegmiller A C,Xu Y,McKenna R W,et al. Immunophenotypic differentiation between neoplastic plasma cells in mature B-cell lymphoma vs plasma cell myeloma[J].Am J Clin Pathol,2007,127(2):176-181.
[6] Bataille R, Jégo G, Robillard N, et al. The phenotype of normal, reactive and malignant plasma cells. Identification of “many and multiple myelomas” and of new targets for myeloma therapy[J].Haematologica,2006,91(9):1234-1240.
[7] Damgaard T, Knudsen L M, Dahl I M, et al. Regulation of the CD56 promoter and its association with proliferation, anti-apoptosis and clinical factors in multiple myeloma[J]. Leuk Lymphoma, 2009,50(2):236-246.
[8] Rawstron A C, Alberto O, Meral B,et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders[J]. Haematologica,2008,93(3) :431-438.
[9] Kobayashi S, Hyo R, Amitani Y, et al. Four-color flow cytometric analysis of myeloma plasma cells[J]. Am J Clin Pathol, 2006,126(6):908-915.
[10] Moreau P, Robillard N, Je?go G,et al. Lack of CD27 in myeloma delineates different presentation and outcome[J]. Br J Haematol, 2006,132(2):168-170.
[11] Cao W,Goolsby C L,Nelson B P, et a1.Instability of immunophenotype in plasma cell myeloma[J].Am J Clin Pathol,2008,129(26):926-933.
[12] Raja K R, Kovarova L, Hajek R. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders[J]. Br J Haematol, 2010,149(3):334-351.
[13] Korde N, Kristinsson S Y, Landgren O. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies[J]. Blood, 2011,117(21):5573-5581.
[14] Paiva B, Vidriales M B, Mateo G, et al. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients[J]. Blood, 2009,14(20), 4369-4372.
[15] Paiva B, Almeida J, Pérez-Andrés M, et al. Utility of Flow Cytometry Immunophenotyping in Multiple Myeloma and Other Clonal Plasma Cell-Related Disorders[J]. Cytometry B Clin Cytom, 2010,78(4):239-252.
[16] Pérez-Persona E, Vidriales M B, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy ofuncertain significance and smoldering MM based on multiparameter flow cytometry analysis of bone marrow plasma cells[J]. Blood, 2007,110, 2586-2592.
[17] Sher T, Miller K C, Deeb G, et al. Plasma cell leukaemia and other aggressive plasma cell malignancies[J]. Br J Haematol,2010,150(4):418-427.
[18] Ocio E M, del Carpio D, Caballero ?, et al. Differential diagnosis of IgM MGUS and WM according to B-lymphoid infiltration by morphology and flow cytometry[J]. Clin Lymphoma Myeloma Leuk, 2011,11(1):93-95.
[19] Lin P, Molina T J, Cook J R, et al. Lymphoplasmacytic lymphoma and other non-marginal zone lymphomas with plasmacytic differentiation[J]. Am J Clin Pathol,2011,136(2):195-210.
[20] Meyerson H J, Bailey J, Miedler J, et al. Marginal zone B cell lymphomas with extensive plasmacytic differentiation are neoplasms of precursor plasma cells[J]. Cytometry B Clin Cytom,2011, 80(2):71-82.
